Literature DB >> 2122929

Cytostasis of different tumours by a murine PPD-reactive CD4+ T lymphocyte clone is mediated by interferon-gamma and tumour necrosis factor alone or synergistically.

M G Wing1, A M Montgomery, C Harley, P J Lachmann.   

Abstract

We have shown that a murine CD4+ PPD-reactive T lymphocyte clone was weakly cytotoxic towards the syngeneic tumour B16 melanoma and MC6A fibrosarcoma which had been coated with PPD using a monoclonal antibody-PPD heteroconjugate. Cell-free supernatants produced by PPD-stimulated T lymphocyte clones were however highly cytostatic for the two tumour targets when assayed over 48-72 h. In this study we have demonstrated good titres of tumour necrosis factor (TNF) and interferon-gamma (IFN-gamma) in the supernatants, which accounted for their observed cytostatic activity on the tumour targets. The high level of cytostasis seen with the B16 melanoma using the supernatants could be attributed to their sensitivity to the cytostatic activity of IFN-gamma; the lower levels of cytostasis seen with the IFN-gamma-resistant MC6A target was the result of IFN-gamma increasing the sensitivity of this target to TNF. Antibodies to IFN-gamma were able to neutralize the majority of the cytostatic activity of the supernatants on both targets, consistent with the role demonstrated for this lymphokine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2122929      PMCID: PMC1535112          DOI: 10.1111/j.1365-2249.1990.tb05428.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  A novel strategy for targeting CD4+ PPD-reactive T cells against tumour cells using PPD monoclonal antibody heteroconjugates.

Authors:  A M Montgomery; M G Wing; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  The killing of tumour cell targets coupled to tuberculin (PPD) by human and murine PPD-reactive T helper clones. I. PPD specificity of killing.

Authors:  A Vyakarnam; P J Lachmann; D Y Sia
Journal:  Scand J Immunol       Date:  1988-03       Impact factor: 3.487

Review 3.  Cellular and humoral mechanisms of cytotoxicity: structural and functional analogies.

Authors:  J D Young; Z A Cohn
Journal:  Adv Immunol       Date:  1987       Impact factor: 3.543

4.  Identification, isolation, and characterization of a novel cytotoxin in murine cytolytic lymphocytes.

Authors:  C C Liu; M Steffen; F King; J D Young
Journal:  Cell       Date:  1987-11-06       Impact factor: 41.582

5.  Noncytocidal mechanisms of action of tumor necrosis factor-alpha on human tumor cells: enhancement of HLA gene expression synergistic with interferon-gamma.

Authors:  P Scheurich; M Krönke; C Schlüter; U Ucer; K Pfizenmaier
Journal:  Immunobiology       Date:  1986-09       Impact factor: 3.144

6.  Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma.

Authors:  V Ruggiero; J Tavernier; W Fiers; C Baglioni
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

7.  Tumor suppression by a lymphokine released into the circulation of mice with delayed hypersensitivity.

Authors:  S B Salvin; J S Youngner; J Nishio; R Neta
Journal:  J Natl Cancer Inst       Date:  1975-11       Impact factor: 13.506

8.  Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon.

Authors:  J L Crane; L A Glasgow; E R Kern; J S Youngner
Journal:  J Natl Cancer Inst       Date:  1978-09       Impact factor: 13.506

9.  The killing of tumour cell targets coupled to tuberculin (PPD) by human and murine PPD-reactive T helper clones. II. Major histocompatibility complex restriction of killing.

Authors:  A Vyakarnam; P J Lachmann
Journal:  Scand J Immunol       Date:  1988-03       Impact factor: 3.487

10.  Granules of cytolytic T-lymphocytes contain two serine esterases.

Authors:  D Masson; M Nabholz; C Estrade; J Tschopp
Journal:  EMBO J       Date:  1986-07       Impact factor: 11.598

View more
  5 in total

1.  Strategies in antibody therapy of cancer.

Authors:  E J Wawrzynczak; A J Davies
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  A novel strategy for targeting CD4+ PPD-reactive T cells against tumour cells using PPD monoclonal antibody heteroconjugates.

Authors:  A M Montgomery; M G Wing; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

3.  Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

Authors:  M G Wing; T Moreau; J Greenwood; R M Smith; G Hale; J Isaacs; H Waldmann; P J Lachmann; A Compston
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

4.  The targeting of T-helper cells and tumourcidal macrophages to a B-cell lymphoma using a PPD-monoclonal antibody heteroconjugate.

Authors:  A M Montgomery; M G Wing; P J Lachmann
Journal:  Immunology       Date:  1992-02       Impact factor: 7.397

5.  Activated T-lymphocytes induce growth inhibition and prostaglandin E2 release from syngeneic glomerular mesangial cells.

Authors:  H H Radeke; B Schwinzer; K Resch
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.